Role of the Russian Heart Failure Society in Defining Views on Assessing the Severity and Implementing Optimal Methods of Treating CHF in the Russian Federation Over 25 years. Review of Registries and Multicenter Clinical Trials
https://doi.org/10.18087/cardio.2024.11.n2754
Abstract
An important objective of the creation of the Society of Experts in Heart Failure (SEHF) was to assess the level of diagnostics and approaches to the treatment of chronic heart failure (CHF) in the Russian Federation (RF), without which it was impossible to bring clinical practice to the optimal level and in consistency with the existing clinical guidelines. Thus, along with the development of Guidelines for the diagnosis and treatment of CHF, a series of registries and multicenter clinical trials (MCTs) was conducted to bring the indexes of real practice closer to the developed Guidelines. Numerous MCTs organized during the 25 years of the SEHF existence have significantly improved the substantiated and recommended therapy for CHF administered by practicing physicians in the Russian Federation. This article overviews the most important registries and MCTs that were conducted during the 25 years of the SEHF work and their effect on CHF diagnostics and treatment in the clinical practice in the RF.
Supporting agencies: No conflict of interest is reported.
About the Author
V. Yu. Mareev
Medical Research and Educational Institute of the Lomonosov Moscow State University
Russian Federation
Russian Federation
dr med. Sciences, Professor, Chief Researcher
Moscow, Russia
References
1. Belenkov Yu.N., Mareev V.Yu., Aseeva O.A., Bologova T.A. How we treat heart failure in real life. Improvement program (IMPROVEMENT-HF). Russian Medical Journal. 2000;8(2):59–64.
2. Belenkov Yu.N., Mareev V.Yu. How do we diagnose and treat heart failure in real clinical practice in the early 21st century? The results of the study IMPROVEMENT HF. Consilium Medicum. 2001;3(2):65–73.
3. Belenkov Yu.N., Mareev V.Yu. On the classification of chronic heart failure at the turn of the century. Russian Heart Failure Journal. 2000;1(3):88–90.
4. Mareev V.Yu. Treatment of heart failure at the turn of the century. Are the provisions of evidence-based medicine becoming evidence for practitioners? Kardiologiia. 2000;40(12):4–11.
5. Cleland J, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. The Lancet. 2002;360(9346):1631–9. DOI: 10.1016/S0140-6736(02)11601-1
6. National guidelines for the diagnosis and treatment of CHF. Russian Heart Failure Journal. 2002;3(6):261–81.
7. Ageev F.T., Gerasimova V.V., Mareev V.Yu., Barsov D.A., Sergeev I.L., Belenkov Yu.N. Use of functional classes in assessing the condition of patients with severe heart failure. Kardiologiia. 1992;32(2):48–51.
8. Yap J, Lim FY, Gao F, Teo LL, Lam CSP, Yeo KK. Correlation of the New York Heart Association Classification and the 6-Minute Walk Distance: A Systematic Review. Clinical Cardiology. 2015;38(10):621–8. DOI: 10.1002/clc.22468
9. Ingle L, Cleland JG, Clark AL. The relation between repeated 6-minute walk test performance and outcome in patients with chronic heart failure. Annals of Physical and Rehabilitation Medicine. 2014;57(4):244–53. DOI: 10.1016/j.rehab.2014.03.004
10. Mareev V.Yu., Ageev F.T., Arutiunov G.P., Koroteev A.V., Revishvili A.Sh., Vasyuk Yu.A. RSSC and OSSN national guidelines on diagnostics and treatment of CHF (second revision). Russian Heart Failure Journal. 2007;8(1):4–41.
11. Mareev V.Yu., Ageev F.T., Arutiunov G.P., Koroteev A.V., Revishvili A.Sh., Belenkov Yu.N. et al. National recommendations of VNOK and SSHF on the diagnostics and treatment of chronic heart failure (third review) Approved by OSSN Conference, December 15, 2009. Russian Heart Failure Journal. 2010;11(1):3–62.
12. Mareev V.Yu., Ageev F.T., Arutyunov G.P., Koroteev A.V., Mareev Yu.V., Ovchinnikov A.G. et al. SEHF, RSC and RSMSIM national guidelines on CHF diagnostics and treatment (fourth revision) Approved at the SEHF Congress on December 7, 2012, at the SEHF Board of Directors meeting on March 31, 2013, and at the RSC Congress on September 25, 2013. Russian Heart Failure Journal. 2013;14(7):379–472.
13. Mareev V.Yu., Fomin I.V., Ageev F.T., Arutiunov G.P., Begrambekova Yu.L., Belenkov Yu.N. et al. Clinical guidelines. Chronic heart failure (CHF). Russian Heart Failure Journal. 2017;18(1):3–40. DOI: 10.18087/rhfj.2017.1.2346
14. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–158. DOI: 10.18087/cardio.2475
15. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L. et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–74. DOI: 10.15829/1560-4071-2020-4083
16. Cohn JN. Prognostic factors in heart failure: poverty amidst a wealth of variables. JACC. 1989;14(3):571–2
17. Cody RJ. Clinical trials of diuretic therapy in heart failure: Research directions and clinical considerations. Journal of the American College of Cardiology. 1993;22(4 Suppl A):A165–71. DOI: 10.1016/0735-1097(93)90484-I
18. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. American Heart Journal. 2000;140(6):840–7. DOI: 10.1067/mhj.2000.110933
19. Kapanadze L.G., Petrukhina A.A., Nasonova S.N., Skvortsov А.А., Mareev V.Yu. The role of hypotension as a factor of unfavorable prognosis in patients with chronic heart failure. Kardiologiia. 2011;51(10):53–60.
20. Mareev Yu.V., Gerasimova V.V., Goriunova T.V., Petrukhina A.A., Danielian M.O., Kapanadze L.G. et al. Factors defining the prognosis in chronic heart failure: role of the QRS width and morphology. Russian Heart Failure Journal. 2012;13(5):255–66.
21. Mareev V.Yu., Kapanadze L.G., Kheimets G.I., Mareev Yu.V. Effect of 24-hour blood pressure and heart rate on the prognosis of patients with reduced and midrange LVEF. Kardiologiia. 2021;61(7):4–13. DOI: 10.18087/cardio.2021.7.n1684
22. Belenkov Yu.N., Mareev V.Yu. Principles of rational treatment of chronic heart failure. - M.: Media Medika;2000. - 266 p.
23. Mareev V.Yu. Design and patient characteristics in the study «FASON ». Russian Heart Failure Journal. 2002;3(2):97–8.
24. Iljina A.V., Mareev V.Yu., Gerasimova V.V., Dzhakhangirov T.Sh., Belenkov Yu.N. Efficacy of therapy with the ACEI fosinopril in patients with CHF combined with type 2 DM (by data of FASON study). Russian Heart Failure Journal. 2005;6(5):181–5.
25. Mareev V.Yu. Pharmacoeconomic evaluation of the use of ACEI in ambulatory patients with heart failure (FASON). Russian Heart Failure Journal. 2002;3(1):38–9.
26. Belenkov Yu.N., Mareev V.Yu. Methods for assessing the severity of CHF and evaluating the results of treatment or twenty treatments or twenty answers to twenty questions in twenty illustrations based on the results of the Russian multicenter study ‘FASON’. - M.: 2002, - 24p.
27. Mareev V.Yu., Danielyan M.O. Optimizing the use of BEtaloc ZOK in patients with CHF in routine medical practicE. Design and results of the study BEZE. Russian Heart Failure Journal. 2005;6(6):251–7.
28. Mareev Yu.V., Mareev V.Yu. P 1730. New clinical assessment scale - useful tool to analysis effect of treatment and prognosis of patients with heart failure. European Journal of Heart Failure. 2016;18(Suppl 1):412. DOI: 10.1002/ejhf.539
29. Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Danielian M.O. The first results of the national epidemiological study - epidemiological examination of patients with CHF in real clinical practice (according to the appeal) - ERA-O-CHF. Russian Heart Failure Journal. 2003;4(3):116–21.
30. Ageev F.T., Danielyan M.O., Mareev V.Yu., Belenkov Yu.N. Patients with chronic heart failure in the Russian ambulatory practice: contingent features, diagnosis and treatment (studies of AGEO-CHF). Russian Heart Failure Journal. 2004;5(1):4–7.
31. Mareev V.Yu., Danielyan M.O., Belenkov Yu.N. Comparative characteristics of patients with CHF in relation to the value of injection fraction by data from the Russian multicenter study EPOCH-A-CHF: once more about the problem of CHF with preserved left ventricular systolic function. Russian Heart Failure Journal. 2006;7(4):164–71.
32. Seredenina E.M., Begrambekova Yu.L., Mareev V.Yu. P 857. Implementation of European guidelines in real practice of congestive heart failure treatment in Russia 2002 – 2012. European Journal of Heart Failure. 2016;18(Suppl 1):191. DOI: 10.1002/ejhf.539
33. Mareev Yu.V., Mareev V.Yu. Characteristics and treatment of hospitalized patients with CHF. Kardiologiia. 2017;57(S4):20–30. DOI: 10.18087/cardio.2433
34. Mareev V.Yu., Seredenina E.M., Mareev Yu.V., Borisov E.N., Begrambekova Yu.L., Tchaikovsky M.E. P 1924. Do patients with midterm HF have profile like HFrEF or HFpEF or they have their individual profile. Data from Russian National Register 2012. European Journal of Heart Failure. 2017;19(Suppl 1):484. DOI: 10.1002/ejhf.833
35. Shlyakhto E.V., Belenkov Yu.N., Boytsov S.A., Villevalde S.V., Galyavich A.S., Glezer M.G. et al. Prospective observational multicenter registry study of patients with heart failure in the Russian Federation (PRIORITET-CHF): rationale, objectives and design of the study. Russian Journal of Cardiology. 2023;28(6):7–14. DOI: 10.15829/1560-4071-2023-5456
36. Shlyakhto E.V., Belenkov Yu.N., Boytsov S.A., Villevalde S.V., Galyavich A.S., Glezer M.G. et al. Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation ‘PRIORITET-CHF’: initial characteristics and treatment of the first included patients. Russian Journal of Cardiology. 2023;28(10):93–103. DOI: 10.15829/1560-4071-2023-5593
37. Kristensen SL, Jhund PS, Lee MMY, Køber L, Solomon SD, Granger CB et al. Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovascular Drugs and Therapy. 2017;31(5–6):545–9. DOI: 10.1007/s10557-017-6754-x
38. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450–6
39. Haseeb MT, Nouman Aslam M, Avanteeka F, Khalid UAR, Zubaer Ahmad D, Senaratne M et al. Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis. Cureus. 2023;15(3):e36392. DOI: 10.7759/cureus.36392
40. Brophy JM, Joseph L, Rouleau JL. β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis. Annals of Internal Medicine. 2001;134(7):550–60. DOI: 10.7326/0003-4819-134-7-200104030-00008
41. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJV, Swedberg K et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. European Heart Journal. 2012;33(22):2782–95. DOI: 10.1093/eurheartj/ehs257
42. Belenkov Yu.N., Mareev V.Yu. The treatment of congestive heart failure in XXI century: questions and lessons of evidence based medicine. Kardiologiia. 2008;48(2):6–16.
43. Belenkov Yu.N., Mareev V.Yu., Skvortsov A.A. Is it always necessary to use triple combination in the treatment of patients with chronic cardiac failure? Choice of the third neurohormonal blocker. Therapeutic Archive. 2008;80(9):5–12.
44. Docherty KF, McMurray JJV. SOLOIST‐WHF and updated metaanalysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. European Journal of Heart Failure. 2021;23(1):27–30. DOI: 10.1002/ejhf.2075
45. Mareev V.Yu., Vygodin V.A., Belenkov Yu.N. DiUretic therapy with Effective doses of oraL diuretics: torasemide (Diuver®) and furosemide in patients with acute exacerbation of Chronic Heart Failure (DUEL– CHF). Russian Heart Failure Journal. 2011;12(1):3–10.
46. Mareev V.Yu., Mareev Yu.V., Vygodin V.A., Belenkov Yu.N. P 1629. Mortality and rehospitalization data from diuretic therapy with effective dosesof oral torasemide and furosemide in treatment of patients with exacerbationof chronic heart failure (DUEL-CHF) trial. European Journal of Heart Failure. 2016;18(Suppl 1):382. DOI: 10.1002/ejhf.539
47. Ageev F.T., Zhubrina E.S., Gilyarevskiy S.R., Mareev V.Yu., Khoseva E.N., Golshmid M.V. Comparative efficacy and safety of chronic torasemide and furosemide therapy in patients with compensated heart failure. Effect on markers of myocardial fibrosis. Russian Heart Failure Journal. 2013;14(2):55–62.
48. Tokareva O.G., Kharitonova E.V., Mareev V.Yu. Effect of coenzyme Q10 used as a part of standard therapy on plasma levels of brain natriuretic peptide in patients with chronic heart failure. Russian Heart Failure Journal. 2014;15(4):232–7.
49. Mareev V.Yu., Minina Yu.V., Begrambekova Yu.L. KUDESan® (3% drops for oral use) in treatment of patieNts with heart failure: efficacy and safety In Combination with standard therapy (KUDESNIC). Design and results of a prospective, randomized, double-blind KUDESNIC study. Russian Heart Failure Journal. 2016;17(4):236–49. DOI: 10.18087/rhfj.2016.4.2257
50. Raizner AE. Coenzyme Q10. Methodist DeBakey Cardiovascular Journal. 2019;15(3):185–91. DOI: 10.14797/mdcj-15-3-185
51. Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. Journal of the American College of Cardiology. 2008;52(18):1435–41. DOI: 10.1016/j.jacc.2008.07.044
52. Kalenikova E.I., Gorodetskaya E.A., Medvedev O.S. The pharmacokinetics of coenzyme Q10. Russian Medical Journal. 2008;16(5):338–40.
53. Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D et al. The Effect of Coenzyme Q10 on Morbidity and Mortality in Chronic Heart Failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure. 2014;2(6):641–9. DOI: 10.1016/j.jchf.2014.06.008
54. Mareev V.Yu., Mareev Yu.V., Begrambekova Yu.L. Coenzyme Q-10 in the treatment of patients with chronic heart failure and reduced left ventricular ejection fraction: systematic review and meta-analysis. Kardiologiia. 2022;62(6):3–14. DOI: 10.18087/cardio.2022.6.n2050
55. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–726. DOI: 10.1093/eurheartj/ehab368
56. World Health Organisation. Hemoglobin concentration for the diagnosis of anemia and assessment of its severity. Vitamin and Mineral Nutrition Information System. Av. at: https://iris.who.int/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?sequence=22.
57. Mareev V.Yu., Begrambekova Yu.L., Mareev Yu.V., Kobalava Zh.D., Karapetyan L.V., Galochkin S.A. et al. Iron deficiency in Russia heart failure patients. Observational cross-sectional multicenter study. Kardiologiia. 2022;62(5):4–8. DOI: 10.18087/cardio.2022.5.n2083
58. Komajda M. The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe Part 2: treatment. European Heart Journal. 2003;24(5):464–74. DOI: 10.1016/S0195-668X(02)00700-5
59. Fomin I.V., Polyakov D.S., Vaisberg A.R. 25 years of chronic heart failure treatment in clinical practice in the Russian Federation - are we doing everything right in 2022? Medical Almanac. 2022;4(73):27–37.
Review
For citations:
Mareev V.Yu. Role of the Russian Heart Failure Society in Defining Views on Assessing the Severity and Implementing Optimal Methods of Treating CHF in the Russian Federation Over 25 years. Review of Registries and Multicenter Clinical Trials. Kardiologiia. 2024;64(11):15-36. (In Russ.) https://doi.org/10.18087/cardio.2024.11.n2754
Views:
479
Email this article 
Post a Comment 
